Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10330050 | 0.91 | SYK (1.00) | SYK | |
| SCHEMBL1235200 | 0.90 | SYK (1.00) | SYK | |
| SCHEMBL1235638 | 0.89 | SYK (1.00) | SYK | |
| SCHEMBL1235431 | 0.89 | SYK (1.00) | SYK | |
| SCHEMBL1234971 | 0.86 | SYK (0.87) | SYK | |
| SCHEMBL10322027 | 0.86 | SYK (1.00) | SYK | |
| SCHEMBL1051630 | 0.85 | SYK (0.80) | SYK | |
| SCHEMBL1058515 | 0.85 | SYK (1.00) | SYK | |
| SCHEMBL10321336 | 0.84 | SYK (1.00) | SYK | |
| SCHEMBL1235761 | 0.84 | SYK (1.00) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722692-B2 | Compounds and compositions as Syk kinase inhibitors | IRM LLC (BM) | 2014-05-13 | — | — | US | claimed |
| US-20120184526-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2012-07-19 | — | — | US | claimed |
| US-8722692-B2 | Compounds and compositions as Syk kinase inhibitors | IRM LLC (BM) | 2014-05-13 | — | — | US | disclosed |
| US-8722692-B2 | Compounds and compositions as Syk kinase inhibitors | IRM LLC (BM) | 2014-05-13 | — | — | US | disclosed |
| US-8722692-B2 | Compounds and compositions as Syk kinase inhibitors | IRM LLC (BM) | 2014-05-13 | — | — | US | disclosed |
| US-20120184526-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2012-07-19 | — | — | US | disclosed |
| US-20120184526-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2012-07-19 | — | — | US | disclosed |
| US-20120184526-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2012-07-19 | — | — | US | disclosed |
| EP-2459558-A2 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011014795-A2 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011014795-A2 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184526-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | SYK, BTK, LYN | SYK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.